Navigation Links
Oxford BioTherapeutics and Boehringer Ingelheim Enter Collaboration to Discover Novel Antibody Targets in Cancer
Date:4/29/2013

OXFORD, England, April 29, 2013 /PRNewswire/ --

Oxford BioTherapeutics (OBT) and Boehringer Ingelheim

(BI) today announce a new alliance focused on the discovery of novel cancer antibody targets that OBT will identify with the help of its OGAP® discovery platform.

Under the collaboration OBT will validate certain targets it has discovered that are compatible with targeting by various antibody drug formats across a range of cancer indications. Following completion of these activities, BI will have the exclusive right to develop and commercialize antibody products for selected programs.

OBT will receive an undisclosed upfront payment and FTE funding for its activities under the collaboration, and will be eligible for certain milestone payments upon the achievement of specified discovery, development and commercialization milestones, as well as royalties on sales of any resulting products.

Christian Rohlff , CEO of OBT, commented: "Selecting the right target is fundamental for the successful development of a first in class antibody product drug and we are delighted to collaborate with a company of the calibre of BI in this exciting area of cancer antibody development."

About Oxford BioTherapeutics

Oxford BioTherapeutics (OBT) is a leading international biotechnology company focused on delivering innovative and cost-effective first-in-class medicines to fulfil major unmet patient needs in the field of cancer. OBT is developing cutting-edge antibody-based cancer medicines, with integrated diagnostics, against novel targets that it has discovered through its unique OGAP® proteomic database. OGAP® represents the world's largest proprietary collections of disease-associated proteins. It contains proteomic data on over 7,500 cancer membrane proteins and proprietary protein disease expression information more than three-qu
'/>"/>

SOURCE Oxford BioTherapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Oxford Performance Materials and Biomet Microfixation Join Forces
2. Oxford University Hospitals NHS Trust and the Bodleian Libraries Select ClinicalKey
3. Oxford Finance Completes $271.4 Million Securitization Transaction
4. Oxford Finance and Silicon Valley Bank Provide $15 Million Senior Credit Facility to NanoString Technologies
5. Oxford Finance Provides $15 Million Senior Secured Credit Facility to Private Equity Backed Healthcare Services Company
6. Oxford BioTherapeutics Appoints C. Glenn Begley as a Senior Clinical Advisor and Non-executive Director
7. Genedata Expressionist for Mass Spectrometry Showcased at 2013 Biotherapeutics Analytical Summit
8. Smith & Nephew Announces Agreement To Acquire Assets Of Healthpoint Biotherapeutics
9. Northwest Biotherapeutics Appoints Pharma Industry Veteran As CEO Of German Subsidiary
10. Healthpoint Biotherapeutics To Create State-of-the-Art Cell Sciences Manufacturing Facility
11. Healthpoint Biotherapeutics to Present at 30th Annual J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 24, 2014 Your cell phone ... modeling lithium-ion battery storage capacity. , New research ... theoretical model created at Lawrence Livermore National ... predicts how carbon components will perform as electrodes. ... the urgent need for higher-performance batteries. Several key ...
(Date:7/24/2014)... , July 24, 2014  Neogen Corporation (Nasdaq: ... future forecasts of its potential revenue from new rodenticide ... to investors and analysts on July 22, 2014, Neogen,s ... analysts regarding this research. "It was my ... about the potential of a new type of rodenticide, ...
(Date:7/24/2014)... BETHESDA, Md. , July 24, 2014  Spherix ... to the fostering and monetization of intellectual property, today ... for the period ending June 30, 2014 on Monday, ... conference call at 10 a.m. ET on Monday, August ... to be led by the company,s CEO, Anthony ...
(Date:7/23/2014)... Emirates (UAE) (PRWEB) July 23, 2014 ... recently announced that its biobanking project, Provia ... Ph.D. to its growing Advisory Board. Scott Wolf ... pleased to have Dr. Vaught onboard with Provia’s ever-expanding ... and expertise that Provia’s management team brings to this ...
Breaking Biology Technology:Getting More Life out of Lithium-ion Batteries 2Neogen comments on SenesTech 2Spherix Schedules Shareholder Update Call 2Provia Laboratories Adds Dr. Jim Vaught, Ph.D., Former Chief of BBRB, to Advisory Board 2Provia Laboratories Adds Dr. Jim Vaught, Ph.D., Former Chief of BBRB, to Advisory Board 3Provia Laboratories Adds Dr. Jim Vaught, Ph.D., Former Chief of BBRB, to Advisory Board 4
... YORK, June 8, 2011 Reportlinker.com announces ... available in its catalogue: ... http://www.reportlinker.com/p0548785/Future-of-White-Biotechnology-in-China.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=NoCategory ... referred to the third wave in biotechnology, ...
... 7, 2011 Vaxart, Inc., a San Francisco biotechnology company ... I clinical trial. This is the first clinical study evaluating ... The trial site is in the United States. ... is demonstrated with one vaccine, we can expect that later ...
... 7, 2011 Infrared Systems International (OTCBB: IFRS) is pleased ... pilot study of its NatuRx™ HIV/AIDS treatment and will push ... AquaLiv concluded a pilot study with two HIV/AIDS patients ... of the first reported AIDS victims on June 5th, 1981. ...
Cached Biology Technology:Reportlinker Adds Future of White Biotechnology in China 2Reportlinker Adds Future of White Biotechnology in China 3Reportlinker Adds Future of White Biotechnology in China 4Reportlinker Adds Future of White Biotechnology in China 5Vaxart Begins First Oral Vaccine Clinical Trial 2Infrared Systems International's Subsidiary, AquaLiv, Inc., Strives to Be a Game Changer in Fight Against HIV/AIDS 2Infrared Systems International's Subsidiary, AquaLiv, Inc., Strives to Be a Game Changer in Fight Against HIV/AIDS 3
(Date:7/24/2014)... brewery has its own microbial terroir, meaning the microbial ... found in the product, creating the final flavor according ... Applied and Environmental Microbiology . This is the ... a sake brewery. , Many sake makers inoculate ... A. Mills of the University of California, Davis, but ...
(Date:7/24/2014)... cleanup experts gathered at NJIT this week for an ... the U.S. Environmental Protection Agency (EPA) to dredge toxic ... River. , The EPA has called the plan, which ... and capping sections of the riverbed, one of the ... would be dredged and disposed off-site. , "We need ...
(Date:7/24/2014)... research into the potato genes that best adapt to ... in rainfall and increased extremes of hot and cold ... in order to create new potato varieties that will ... seeking to find out how the current potato varieties ... higher and lower temperatures. , This research is part ...
Breaking Biology News(10 mins):The microbes make the sake brewery 2Experts Weigh the Pros and Cons of a $1.7 Billion EPA Cleanup Plan for the Passaic River at an NJIT 2Neiker-Tecnalia is researching the potato genes that best adapt to climate change 2
... Mich.---By mimicking the structure of the silk moth,s antenna, ... better nanopore---a tiny tunnel-shaped tool that could advance understanding ... A paper on the work is newly published ... headed by Michael Mayer, an associate professor in the ...
... developed by researchers in Temple University,s College of Science ... cancer. The leptin receptor antagonist peptide, developed by ... attractive option for triple negative breast cancer treatment, especially ... their findings online in the European Journal of ...
... environmental researchers from across North America have been ... Based at Stanford University,s Woods Institute for the ... 1998 to help academic scientists make their knowledge ... program selects up to 20 mid-career academic environmental ...
Cached Biology News:Silk moth's antenna inspires new nanotech tool with applications in Alzheimer's research 2New peptide could be effective treatment for triple negative breast cancer 220 researchers selected as 2011 Leopold Leadership Fellows 220 researchers selected as 2011 Leopold Leadership Fellows 320 researchers selected as 2011 Leopold Leadership Fellows 4
The S. cerevisiae Hansen strains are the parental yeast strains from which the deletions were derived....
The DNA DipStick Kit is ideal for estimating nucleic acid concentrations and approximate yields. Works with ss- and ds-DNA, RNA, and oligonucleotides at concentrations as low as 0.1 ng/l....
... electronic from BRAND adds ergonomics and ... the only electronic, motor-driven repeating pipette ... including BRAND PD-Tip syringe tips, Eppendorf ... Tips,and VWRbrand Combi-Syringes. Select virtually any ...
The pYES2 vector is designed for native expression of your protein of interest in S. cerevisiae. It contains the URA3 gene for selection in yeast and 2 origin for high-copy maintenance....
Biology Products: